Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2014-04-30 | William S. Reardon, CPA: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides the Trustees of the Fund with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. ... He serves on the Valuation and Audit Committees of the Fund. ... The members of the Fund's Audit Committee are Mr. Pohotsky, Mr. Reardon, Dr. Reinhardt and Ms. Stebbins. ... The members of the Fund's QLCC are Dr. Jain, Mr. Pohotsky and Mr. Reardon. Mr. Reardon is the Chairman of the Fund's QLCC. ... Compensation Table ... William S. Reardon, CPA ... Total Compensation ... $61,500. |
| 2015-04-20 | William S. Reardon, CPA (68) 100 Federal Street, 19th Floor, Boston MA 02110 Trustee, HQH, HQL and THQ; Member of each Fund's Valuation, Audit and Qualified Legal Compliance Committees. Compensation Table: Total Compensation from All Funds in Fund Complex Paid to Trustees $85,000. |
| 2016-04-18 | William S. Reardon, CPA: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides each Fund with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. He serves on the Valuation and Audit Committees of each Fund. |
| 2017-04-18 | William S. Reardon, CPA: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides each Fund with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. He serves on the Valuation Committee and as Chair of the Audit Committee of each Fund. ... Compensation Table ... William S. Reardon, CPA ... Total Compensation from All Funds in Fund Complex Paid to Trustees $100,000. |
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-20 | William S. Reardon, CPA (68) 100 Federal Street, 19th Floor, Boston MA 02110 Trustee, HQH, HQL and THQ; Member of each Fund's Valuation, Audit and Qualified Legal Compliance Committees. Compensation: $85,000 |
| 2016-04-18 | William S. Reardon, CPA: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides each Fund with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. Until 2002, Mr. Reardon was a business assurance partner in PwC's Boston office and leader of the Life Sciences Industry Practice for New England and the Eastern U.S., working closely with many of the Firm's public clients in SEC-registered equity, convertible and R&D limited partnership offerings and many initial public offerings. He serves on the Valuation and Audit Committees of each Fund. William S. Reardon, CPA (69) 100 Federal Street, 19th Floor, Boston MA 02110: Trustee, HQH, HQL, THQ and THW; Member of each Fund's Valuation, Audit and Qualified Legal Compliance Committees. Compensation: $101,418. |
| 2017-04-18 | William S. Reardon, CPA: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides the Fund with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. Until 2002, Mr. Reardon was a business assurance partner in PwC's Boston office and leader of the Life Sciences Industry Practice for New England and the Eastern U.S., working closely with many of the Firm's public clients in SEC-registered equity, convertible and R&D limited partnership offerings and many initial public offerings. He serves on the Valuation Committee and as Chair of the Audit Committee of the Fund. From 1998-2000 he served on the Board of the Emerging Companies Section of the Biotechnology Industry Organization ("BIO") and from 2000 to 2002 he served on the Board of Directors of the Massachusetts Biotechnology Council ("MBC"). During his professional career, he was a frequent speaker at BIO conferences and MBC Industry meetings on issues affecting biotechnology companies. He currently also serves as a board member and audit committee chair of a development-stage public company, Idera Pharmaceuticals. Mr. Reardon is member of the American Institute of CPAs and the Massachusetts Society of CPAs, with an MBA from Harvard Business School and a BA in East Asian History from Harvard College. |
Data sourced from SEC filings. Last updated: 2026-02-03